Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NBIX Stock Forecast 2026-2027
$178.24
Current Price
$17.92B
Market Cap
Buy 24
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to NBIX Price Targets
+40.6%
To High Target of $250.65
+12.2%
To Median Target of $200.00
-19.2%
To Low Target of $144.00
NBIX Price Momentum
+2.3%
1 Week Change
+7.9%
1 Month Change
+33.5%
1 Year Change
+25.7%
Year-to-Date Change
-0.3%
From 52W High of $178.75
+45.9%
From 52W Low of $122.14
📊 TOP ANALYST CALLS
Did NBIX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Neurocrine Biosciences is one of their latest high-conviction picks.
Latest NBIX Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, NBIX has a bullish consensus with a median price target of $200.00 (ranging from $144.00 to $250.65). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $178.24, the median forecast implies a 12.2% upside. This outlook is supported by 24 Buy, 4 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NBIX Analyst Ratings
24
Buy
4
Hold
0
Sell
NBIX Price Target Range
Low
$144.00
Average
$200.00
High
$250.65
Current: $178.24
Latest NBIX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NBIX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 7, 2026 | RBC Capital | Brian Abrahams | Outperform | Maintains | $195.00 |
| Jun 2, 2026 | Goldman Sachs | Corinne Johnson | Buy | Reinstates | $213.00 |
| May 29, 2026 | RBC Capital | Brian Abrahams | Outperform | Maintains | $183.00 |
| May 22, 2026 | Bernstein | Outperform | Initiates | $N/A | |
| May 8, 2026 | JP Morgan | Overweight | Maintains | $N/A | |
| May 7, 2026 | Truist Securities | Buy | Maintains | $N/A | |
| May 6, 2026 | Citigroup | Buy | Maintains | $N/A | |
| May 6, 2026 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| May 6, 2026 | RBC Capital | Outperform | Maintains | $N/A | |
| May 6, 2026 | Piper Sandler | Overweight | Maintains | $N/A | |
| May 6, 2026 | Guggenheim | Buy | Reiterates | $N/A | |
| May 6, 2026 | Wedbush | Outperform | Maintains | $N/A | |
| Apr 22, 2026 | Leerink Partners | Outperform | Maintains | $N/A | |
| Apr 10, 2026 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Apr 7, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Apr 7, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Apr 7, 2026 | Wedbush | Outperform | Maintains | $N/A | |
| Apr 7, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Apr 6, 2026 | Needham | Buy | Reiterates | $N/A | |
| Mar 12, 2026 | JP Morgan | Overweight | Maintains | $N/A |
Neurocrine Biosciences Inc. (NBIX) Competitors
The following stocks are similar to Neurocrine Biosciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
NBIX
Neurocrine
mkt cap
17.52B
Neurocrine Biosciences Inc. (NBIX) Financial Data
Neurocrine Biosciences Inc. has a market capitalization of $17.92B with a P/E ratio of 27.3x. The company generates $3.10B in trailing twelve-month revenue with a 21.6% profit margin.
Revenue growth is +42.2% quarter-over-quarter, while maintaining an operating margin of +22.8% and return on equity of +22.5%.
Valuation Metrics
Market Cap
$17.92B
Enterprise Value
$17.07B
P/E Ratio
27.3x
PEG Ratio
0.0x
Price/Sales
5.8x
Growth & Margins
Revenue Growth (YoY)
+42.2%
Gross Margin
+98.3%
Operating Margin
+22.8%
Net Margin
+21.6%
EPS Growth
+2,405.1%
Financial Health
Cash/Price Ratio
+7.3%
Current Ratio
2.9x
Debt/Equity
13.6x
ROE
+22.5%
ROA
+11.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Neurocrine Biosciences Inc. (NBIX) Business Model
About Neurocrine Biosciences Inc.
What They Do
Biopharmaceutical company focused on neuroscience treatments.
Business Model
Neurocrine Biosciences generates revenue through the discovery, development, and commercialization of specialized treatments for neurological and endocrine disorders. Their flagship product, INGREZZA, along with partnered products and a strong pipeline of investigational therapies, contributes to their income stream.
Additional Information
Founded in 1992 and headquartered in San Diego, Neurocrine is engaged in advancing therapies for complex movement disorders and psychiatric conditions. They have a robust pipeline including drugs for major depressive disorder, schizophrenia, and metabolic conditions, highlighting their commitment to innovation in the biopharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
2,000
CEO
Mr. Kyle W. Gano Ph.D.
Country
United States
IPO Year
1996
Website
www.neurocrine.comNeurocrine Biosciences Inc. (NBIX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Neurocrine (NBIX) Upgraded to Strong Buy: What Does It Mean for the Stock?
Neurocrine (NBIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Jul 08, 2026
By Zacks Equity Research
Tale of the Tape
Reasons Why Investors Should Consider Betting on Neurocrine Stock
NBIX builds on Ingrezza's momentum with pipeline advances and the Soleno acquisition, strengthening its long-term neuroscience growth strategy.
Jul 06, 2026
By Zacks Equity Research
Analyst Blog
Neurocrine Biosciences (NBIX) Is Up 6.46% in One Week: What You Should Know
Does Neurocrine Biosciences (NBIX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Jul 01, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
NBIX enhances its neuroscience growth strategy by advancing its pipeline and acquiring Soleno, building on Ingrezza's market momentum.
Why It Matters
NBIX's pipeline advancements and Soleno acquisition signal potential revenue growth and increased market share in neuroscience, positively influencing investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Neurocrine Biosciences (NBIX) maintains a Buy rating as Q1 2026 revenues rose 44% to $811M, driven by Ingrezza, Crenessity, and Vykat. Stock valuation reflects high growth with a forward P/S of ~5.1x and P/E of ~30x.
Why It Matters
Neurocrine's strong revenue growth and successful product performance signal robust future earnings, making it a compelling investment opportunity amid high-growth expectations.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Neurocrine Biosciences has launched a Phase 2 clinical study for crinecerfont in children under 4 with classic congenital adrenal hyperplasia, expanding its use beyond approved age groups.
Why It Matters
The initiation of a Phase 2 study for crinecerfont in young children could expand Neurocrine's market potential and drive future revenue growth, impacting stock performance positively.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Neurocrine Biosciences (NBIX) is being evaluated as a potential top stock pick for momentum investors.
Why It Matters
Neurocrine Biosciences' potential as a momentum stock could indicate future price appreciation, attracting investors seeking growth opportunities and influencing market sentiment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
NBIX, MYRG, XYZ, DK, and DY exhibit strong price strength, positive estimate revisions, and solid fundamentals as they approach the second half of the year.
Why It Matters
Strong relative price strength and positive estimate revisions for NBIX, MYRG, XYZ, DK, and DY indicate potential for growth, suggesting these stocks may outperform the market.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Neurocrine (NBIX) is projected to deliver strong returns due to its robust growth characteristics.
Why It Matters
Neurocrine's strong growth potential suggests increased profitability, attracting investor interest and possibly driving up stock prices.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About NBIX Stock
What is Neurocrine Biosciences Inc.'s (NBIX) stock forecast for 2027?
Based on our analysis of 7 Wall Street analysts, Neurocrine Biosciences Inc. (NBIX) has a median price target of $200.00. The highest price target is $250.65 and the lowest is $144.00.
Is NBIX stock a good investment in 2027?
According to current analyst ratings, NBIX has 24 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $178.24. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NBIX stock?
Wall Street analysts predict NBIX stock could reach $200.00 in the next 12 months. This represents a 12.2% increase from the current price of $178.24. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Neurocrine Biosciences Inc.'s business model?
Neurocrine Biosciences generates revenue through the discovery, development, and commercialization of specialized treatments for neurological and endocrine disorders. Their flagship product, INGREZZA, along with partnered products and a strong pipeline of investigational therapies, contributes to their income stream.
What is the highest forecasted price for NBIX Neurocrine Biosciences Inc.?
The highest price target for NBIX is $250.65 from at , which represents a 40.6% increase from the current price of $178.24.
What is the lowest forecasted price for NBIX Neurocrine Biosciences Inc.?
The lowest price target for NBIX is $144.00 from at , which represents a -19.2% decrease from the current price of $178.24.
What is the overall NBIX consensus from analysts for Neurocrine Biosciences Inc.?
The overall analyst consensus for NBIX is bullish. Out of 7 Wall Street analysts, 24 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $200.00.
How accurate are NBIX stock price projections?
Stock price projections, including those for Neurocrine Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 9, 2026 9:00 AM UTC